The Effect of Mifepristone on the Expression of Cervical Prostaglandin EP3 Receptors

University of Southern California18 enrolled

Overview

The purpose of this study is to determine the effect of mifepristone on the expression of three cervical EP3 receptor isoforms (EP3-2, EP3-3 and EP3-6) in pregnant women ≤63 days gestational age.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Cervical Prostaglandin EP3 Receptors Pregnancy

Interventions

MifepristoneDRUG

Administration of 200 mg of mifepristone orally 48 hours prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity

Non-treatmentOTHER

Non-treatment prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * good general health * ≥18 years old * seeking termination of a viable intrauterine pregnancy of ≤63 days, without any evidence of a threatened or spontaneous abortion Exclusion Criteria: * medical problems * confirmed or suspected ectopic pregnancy * having taken medications in the seven days prior to enrollment that would affect PG synthesis or metabolism of mifepristone

Locations (1)

Women's and Children's Hospital, Reproductive Research Center

Los Angeles, California, United States

Outcomes

Primary Outcomes

The amount of expression of EP3 receptor mRNA levels in cervical tissue after the administration of mifepristone

Time frame: 48 hours after the administration of mifepristone

Secondary Outcomes

The degree of cervical dilation after the administration of mifepristone

Time frame: 48 hours after the administration of mifepristone

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.